Business context and reporting period
Important identity/period discrepancy: The supplied filing is for IsoRay, Inc., not Perspective Therapeutics, Inc. It reports the quarter ended September 30, 2017, IsoRay’s first quarter of fiscal 2018—not 2017 Q1. The filing describes IsoRay as a manufacturer of Cesium-131 brachytherapy seeds.
Financial results and liquidity
Unless noted otherwise, amounts are in U.S. dollars; financial statement amounts below are in millions.
- Revenue: $1.211 million, up 12% from $1.081 million in the prior-year quarter.
- Profitability: Gross profit was $0.265 million versus $0.048 million; gross margin improved to about 22% from 4%. Operating loss was $1.552 million versus $1.575 million. Net loss was $1.546 million versus $1.498 million; loss per share was $0.03 in both periods.
- Expenses: Operating expenses rose 12% to $1.817 million. R&D was $0.362 million, sales and marketing $0.614 million, and general and administrative $0.841 million.
- Cash flow: Operating cash use was $1.661 million versus $1.353 million. Investing cash use was $0.315 million. Cash declined $1.976 million to $3.956 million.
- Liquidity and debt: Cash and cash equivalents plus certificates of deposit totaled $7.256 million at September 30. Working capital was $7.799 million and the current ratio 8.31. Total liabilities were $1.635 million, including a $0.568 million asset retirement obligation; the filing reports no conventional borrowings.
- Margins and concentration: One physician group accounted for about 26% of sales; five customers accounted for about 54% of revenue.
Changes versus prior comparable quarter
Revenue increased 12%, while cost of product sales fell 8%, lifting gross margin substantially. Operating loss narrowed slightly, but net loss widened because non-operating income fell to $0.006 million from $0.077 million. Operating cash use increased by $0.308 million. The company attributed sales growth to a fuller sales team and refreshed marketing efforts, and improved product costs to procurement savings, lower staffing costs, and production employees shifting to R&D work.
Outlook, commentary, risks and unusual items
- Management projected at least 20% revenue growth for fiscal 2018 compared with fiscal 2017, while acknowledging first-quarter revenue growth was 12%. It said existing cash and certificates of deposit were expected to cover projected operating needs for the rest of fiscal 2018, assuming no extraordinary expenses.
- Management estimated cash-flow break-even in three to five years if its growth strategy succeeds; it cautioned that the targeted growth is not assured.
- The company said it might need to raise capital within six to nine months to maintain its NYSE American listing under its projected budget and revenue assumptions. Future financing could dilute shareholders.
- Management expected to spend approximately $0.260 million over the following 11 months on production automation. A new production and administration facility was designed, but construction depended on obtaining financing.
- Cesium-131 supply arrangements included a Russian supplier contract extended through December 31, 2018, and a consignment/manufacturing arrangement expected to provide over 4,000 curies over ten years; the filing notes there is no assurance the arrangements will continue for that period.
- A shareholder derivative lawsuit was dismissed on October 19, 2017, and the matter was reported resolved. A post-quarter advertising agreement provided for $120,000 cash compensation and warrants, including 250,000 immediately vested warrants and 250,000 additional warrants after 90 days.
- Controls and procedures were assessed as effective, with no material change in internal control over financial reporting reported.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q names IsoRay, Inc., not Perspective Therapeutics, Inc.
- Confirm the intended reporting period: the filing covers the quarter ended September 30, 2017, in fiscal 2018.
- Review the cash runway and potential NYSE American listing risk against actual subsequent financing and operating results.
- Assess whether the 20% fiscal-year revenue-growth target and projected three-to-five-year path to cash-flow break-even were achieved.
- Evaluate dependence on a small customer base and the continuity of Cesium-131 supply arrangements.